Gene Therapy Launches Depend on More Than Approval

Getting a gene therapy approved is only part of the challenge. The harder test often begins afterward, when manufacturers, providers, payors and families all have to move through a process that leaves very little room for delay. A missed authorization step, unclear reimbursement pathway or breakdown in communication can slow treatment at the exact moment patients are racing against disease progression or eligibility timelines.

That is why pharmacy partners have taken on a much larger role in gene therapy launches.

These therapies are expensive, medically complex and highly time sensitive. Biotech companies are no longer looking for a pharmacy that simply dispenses a product. They need a partner that can keep access moving when insurance requirements become complicated, documentation is incomplete or benefit structures overlap between pharmacy and medical coverage. In many cases, the pharmacy partner becomes the operational center holding the process together.

The challenge is coordination. Manufacturers of gene therapies, the prescribers, specialty pharmacies, payors, hospitals and patients' families are all working on separate timelines. As communication breaks down between these disparate entities, delays begin to pile up at an alarming rate. Manufacturers launching therapies want the providers of their therapies to offer transparency into the status of each case, the obstacle delaying it, and the person accountable for moving the case to the next step. Without structure like that, access issues can quietly arise and compound until the appropriate time window for treatment can no longer be reclaimed.

Timing is of greater importance in gene therapy than it is for many standard specialty drug categories. Some patients are operating under age limitations; some will eventually lose ground in the course of their disease to the window for treatment; even a logistical delay can have a clinical impact. This kind of pressure means that responsiveness means something different; it means the extent to which a company can quickly assemble families, providers, and payers so that the care plan doesn't fall apart.

There is also the product-handling side, which carries its own level of complexity. Many cell and gene therapies require ultra-cold storage, cryogenic handling, strict chain-of-custody controls and highly specific shipping conditions. Those are not operational details companies can afford to treat casually. If handling breaks down, patient access breaks down with it. Providers need confidence that products will arrive correctly managed and ready for use without constant follow-up calls or fragmented updates.

Rare disease experience matters here too. Families navigating gene therapy are often already dealing with exhausting care journeys before treatment even begins. Pharmacy teams that understand how to support those patients while still managing reimbursement pressure and logistical complexity tend to become much more valuable to manufacturers over time.

Orsini has built its gene therapy pharmacy model around those realities. Its Cell and Gene Therapy Center of Excellence has been operating since 2017, supporting benefit verification, reimbursement coordination and therapy access across multiple programs. The company also brings experience with dual-benefit contracting, letter-of-agreement negotiations, ultra-cold and cryogenic product handling and broader rare disease pharmacy support. For biotechnology companies trying to move patients from approval to treatment without losing momentum along the way, that operational coordination has become increasingly important.